Easy-to-use blood thinners likely to replace Coumadin
February 07, 2012
For atrial fibrillation patients at risk for stroke
MAYWOOD, Ill. -- Within a few years, a new generation of easy-to-use blood-thinning drugs will likely replace Coumadin for patients with irregular heartbeats who are at risk for stroke, according to a journal article by Loyola University Medical Center physicians.
Unlike Coumadin, the new drugs do not require patients to come in to the clinic on a regular basis to check the dose. Nor do the drugs require extensive dietary restrictions.
First author Sarkis Morales-Vidal, MD, and colleagues describe the new drugs in a review article in the February issue of the journal Expert Reviews. Co-authors are Michael J. Schneck, MD, Murray Flaster, MD, and José Biller, MD. All are in the Department of Neurology, Stroke Program, of Loyola University Chicago Stritch School of Medicine. Biller is department chair.
The new drugs include rivaroxaban (Xarelto®), dabigatran etexilate (Pradaxa®) and apixaban (Eliquis®). They do not share the disadvantages of Coumadin, and may provide equal or superior prevention against clots, Morales and colleagues write.
Atrial fibrillation is the most common form of irregular heartbeat, and a major cause of stroke in the elderly. Electrical signals, which regulate the heartbeat, become erratic. Instead of beating regularly, the upper chambers of the heart quiver. Not all the blood gets pumped out, so clots can form. The clots can migrate to the brain and cause strokes.
More than 3 million Americans have atrial fibrillation, and the number is increasing, due in part to the aging population.
Coumadin's generic name is warfarin. For more than 30 years, the drug had been the only anticoagulant for primary and secondary stroke prevention in patients with atrial fibrillation. But the Food and Drug Administration recently approved dabigatran and rivaroxaban to reduce the risk of stroke and blood clots in patients with atrial fibrillation that is not caused by a heart valve problem. The FDA is considering an application to approve apixaban for the same use.
Coumadin must be carefully monitored. If the dose is too high, a patient could experience excessive bruising and be at higher risk for brain hemorrhages. If the dose is too low, the drug would be ineffective in preventing blood clots. Patients typically must come in at least once a month for a blood test to determine whether the dose needs to be adjusted. Some patients have to come in as often as twice a week.
Coumadin patients also must restrict their diets. For example, they should consume only small amounts of cranberry juice and alcohol and not eat large amounts of foods that are rich in vitamin K, such as spinach, brussels sprouts and green tea.
Disadvantages of the new medications include the limited clinical experience and lack of antidotes, the researchers wrote. The newer drugs are more expensive than Coumadin, but reduce the cost of patient monitoring and blood testing, Morales said.
Dabigatran is an effective alternative to Coumadin for stroke prevention in patients with non-valvular atrial fibrillation. Rivaroxaban is another promising alternative for those patients. Apixaban appears to be better than aspirin for stroke prevention in atrial fibrillation patients who are not candidates for Coumadin therapy, Morales and colleagues wrote.
The authors predict that within the next few years, the new drugs will likely replace Coumadin for long-term anticoagulation in selective patients with non-valvular atrial fibrillation.
Loyola University Health System
Related Atrial Fibrillation Current Events and Atrial Fibrillation News ArticlesOff-label use of device to prevent stroke in a-fib patients is prevalent, potentially dangerous
The Lariat device, which has been cleared by the U.S. Food and Drug Administration (FDA) for soft tissue approximation (placement of a suture) during surgical procedures, is associated with a significant incidence of death and urgent cardiac surgery during its frequent off-label use to prevent stroke in patients with the irregular heartbeat known as atrial fibrillation. Digoxin increases the risk of death in patients with heart problems
There is conflicting evidence about whether digoxin, a drug that has been used worldwide for centuries to treat heart disease, might contribute to an increase in deaths in patients with atrial fibrillation (AF) or congestive heart failure (CHF).Atrial fibrillation increases risk of only 1 type of heart attack
Refining the results of a 2013 study, researchers have found that atrial fibrillation, or irregular heartbeat, is associated with only one type of heart attack - the more common of the two types. 'Motion-tracking' MRIs reveal harbingers of stroke in people with heart rhythm disorder
Stroke is a frequent and dreaded complication of atrial fibrillation. But predicting which of the estimated six million Americans with a-fib are at highest risk has long challenged physicians weighing stroke risk against the serious side effects posed by lifelong therapy with warfarin and other blood thinners. Atrial fibrillation recurrence lower with sleep apnea treatment
The use of continuous positive airway pressure was associated with a significant reduction in the recurrence of atrial fibrillation in patients with obstructive sleep apnea.Study identifies factors linked to greater adherence to use of anticoagulant
Among patients with atrial fibrillation who filled prescriptions for the anticoagulant dabigatran at Veterans Health Administration sites, there was variability in patient medication adherence across sites, with appropriate patient selection and pharmacist-led monitoring associated with greater adherence to the medication.Adherence to blood thinner best with pharmacist management, Stanford researcher says
Patients are more likely to take a new type of blood thinner correctly and without missing doses when they are managed by pharmacists, rather than only by doctors or nurses, according to a study co-authored by a researcher at the Stanford University School of Medicine. Some atrial fibrillation patients receive unnecessary blood thinners
About a quarter of all atrial fibrillation (AF) patients at the lowest risk for stroke receive unnecessary blood thinners from cardiology specialists, according to UCSF researchers, and these providers must be made aware of the resulting potential health risks.New Waldenstrom's drug shows sustained benefit at two years
The most recent results from a clinical trial show that ibrutinib, a newly approved drug for Waldenstrom's Macroglobulinemia, continued to control the rare blood cancer, with 95 percent of patients surviving for two years, report investigators from Dana-Farber Cancer Institute.Deaths from cardiovascular disease increase globally while mortality rates decrease
As the global population pushes past 7 billion and more people reach old age, the number of deaths from cardiovascular diseases is on the rise.
More Atrial Fibrillation Current Events and Atrial Fibrillation News Articles
Beat Your A-Fib: The Essential Guide to Finding Your Cure: Written in everyday language for patients with Atrial Fibrillation|
by Steve S Ryan PhD (Author), Patti J Ryan (Contributor)
Beat Your A-Fib: The Essential Guide to Finding Your Cure by Steve S. Ryan, PhD
Atrial Fibrillation (A-Fib) is the most common cardiac arrhythmia (abnormal heart rhythm) seen by physicians. Many patients suffering from Atrial Fibrillation have three strikes against them:
1. Their "quality of life" has deteriorated; they are scared or frightened.
2. Many experience side effects from the common drug therapies or simply do not want to live on medication; a cure for their A-Fib hasn't been discussed.
3. Patient information is often out-of-date, incomplete or biased toward a specific pharmaceutical or treatment; much information about new treatment options is written in the language of scientists and doctors.
The author, Dr. Steve Ryan, PhD, a former A-Fib patient,...
Atrial Fibrillation: What You Need to Know: A Beginner's Guide for Patients and Caregivers (Health Matters)|
by Eternal Spiral Books, http://EternalSpiralBooks.com
++The Fifth Edition, published September 8, 2014, is now available, with updates on the latest information on atrial fibrillation, including the latest news on dabigatran, (Pradaxa), and rivaroxaban, (Xarelto), two of the blood thinning medications (anticoagulants) often prescribed for patients with atrial fibrillation, plus news on the drug digoxin, and the effectiveness of catheter ablation for AFib.
Atrial Fibrillation is a particular type of irregular heart beat which can have dangerous consequences to your health if left untreated. People with atrial fibrillation, commonly referred to as AF or AFib, are more prone to blood clots, which can lead to heart attack, stroke or even death.
Fortunately, there are a number of effective treatments available for...
Disease: Heart and Health, Energy healing, Heart disease, Disease Treatment (Holistic Healing, Spirit Healing, Healing Book 1)|
by Spirit O' Universe
Cure your Illness! Leave the agonies of Heart Palpitation Behind!
You have all you need to get healthy again! Find out How!
Today only, get this science-packed reference guide for just $0.99. Regularly priced
at $2.99. Read on your PC, Mac, smart phone, tablet or Kindle device.
Learn the symptoms of Atrial Fibrillation and the many natural treatment alternatives you can choose from to stop or even reverse the progression of this disease. You’ll learn the potent healing power of Natures gifts hidden in fruits, vegetables and other foods. You’ll find valuable information about prescription drugs’ and doctor-prescribed medicines’ severe side effects. You’ll be well prepared to decide and choose cost-effective natural treatment...
A Life on Hold: Crossing Paths with Atrial Fibrillation|
by Kevin J Kauffman (Author)
You're going about your daily routine when you suddenly feel an odd squirming in your chest. You quickly realize that it is your heart, flopping around like a fish out of water. What do you do? You probably panic! Maybe you also experience dizziness, nausea, or shortness of breath, or maybe you have no other symptoms at all. But it's still very scary because... it's your heart! This is how chronic atrial fibrillation starts for many of us, and those who develop it often have little to no prior medical history to speak of. Once the demon a-fib has set in, though, we soon find our lives redirected down a dark uncharted path, our days consumed by vain attempts to divine the elusive origins of this mysterious malady as we desperately seek a panacea that can give us back our "normal"... or...
The Magnesium Miracle (Revised and Updated Edition)|
by Carolyn Dean (Author)
REVISED AND UPDATED 2014 EDITION
Magnesium is an essential nutrient, indispensable to your health and well-being. By adding this mineral to your diet, you are guarding against—and helping to alleviate—such threats as heart disease, stroke, osteoporosis, diabetes, depression, arthritis, and asthma. But despite magnesium’s numerous benefits, many Americans remain dangerously deficient. Updated and revised throughout with the latest research, featuring an all-new Introduction, this amazing guide explains the vital role that magnesium plays in your body and life. Inside you will discover
• newly available magnesium supplements that the body absorbs more efficiently
• how calcium can increase the risk of heart disease—and how magnesium can lower it
Conquer Your A-Fib: How To Beat Atrial Fibrillation|
Conquer your a-fib is a comprehensive guidebook for this very common arrhythmia. Containing a wealth of information and strategies for overcoming a-fib it covers:
An introduction to a-fib, what it is and how it can be treated.
Several causes of atrial fibrillation that you may not be aware of.
Dietary and chemical triggers for a-fib
Nutritional deficiencies as a potential trigger for episodes
Modifiable risk factors for a-fib which can reduce and even cure your arrhythmia.
Real life cases of people who have beaten a-fib.
Atrial Fibrillation (OxCard Library) (Oxford Cardiology Library)|
by Mohammad Shenasa (Editor), A. John Camm (Editor)
Atrial Fibrillation is becoming a twenty-first century epidemic. It remains the most common form of sustained arrhythmia with significant mortality, morbidity and cost to the health care system. It is the most common cause of hospital admissions among all arrhythmias. Its prevalence increases with the aging population and is often associated with many other cardiac and noncardiac conditions, most notably congestive heart failure, hypertension, diabetes, and coronary artery disease. Although significant progress in understanding the epidemiology, natural history and mechanism has been made, the antiarrhythmic therapy in patients with Atrial Fibrillation is less satisfactory.
Management of Atrial Fibrillation: A Practical Approach is the perfect pocket guide for those who care for...
A Patient's Guide to Heart Rhythm Problems (A Johns Hopkins Press Health Book)|
by Todd J. Cohen (Author)
Heart rhythm problems can be a matter of life or death. In this easy-to-read guide, Dr. Todd Cohen provides comprehensive information to help people with heart rhythm problems (arrhythmias) get an accurate diagnosis and appropriate treatment. Dr. Cohen tells readers what they need to know about palpitations, rapid heart rhythms (tachycardias), slow heart rhythms (bradycardias), cardiac arrest, and other conditions related to irregular heartbeats.With the goal of informing and empowering heart patients, Dr. Cohen describes the heart’s basic function, the various conditions associated with arrhythmia, and recommended courses of treatment. He discusses such procedures as tilt table testing, electrophysiology studies, catheter ablation, and device implantation (including cardiac monitors,...
Atrial Fibrillation Therapy (Current Cardiovascular Therapy)|
by Gheorghe-Andrei Dan (Editor), Antoni Bayés de Luna (Editor), John Camm (Editor)
The paradigm for atrial fibrillation (AF) management has changed significantly in recent years. A new era has begun for the prevention of one of the most tremendous complication of AF, stroke. Prevention of ischemic stroke in AF patients with oral anticoagulants represents a huge challenge because of the narrow therapeutic change of these drugs, interindividual and intraindividual variability, and the unsatisfactory time in therapeutically range (TTR) with this type of medication.New guidelines have emerged as a result of new mechanisms for initiation and perpetuation for pharmacotherapy to cure AF and trials with new classes of antithrombotic drugs are ongoing. The treatment of AF is still in its infancy, but recent research is revealing how it can be applied with optimal efficacy. This...
Medifocus Guidebook on: Atrial Fibrillation|
by Inc. Medifocus.com (Author)
The Medifocus Guidebook on Atrial Fibrillation is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Atrial Fibrillation, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Atrial Fibrillation, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts, institutions, and...